title: Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
authors.forename: Claudia
authors.initials: C
authors.lastname: Stöllberger
authors.forename: Jörg
authors.initials: J
authors.lastname: Slany
authors.forename: Michael
authors.initials: M
authors.lastname: Brainin
authors.forename: Josef
authors.initials: J
authors.lastname: Finsterer
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D017257:Ramipril / Q000494:pharmacology; D020521:Stroke / Q000150:complications* / Q000517:prevention & control*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D005343:Fibrinolytic Agents; D001262:Atenolol; D019808:Losartan; D017257:Ramipril